Flexible Dosing of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Initial Results From the Real-World–Simulating Expanded Access Protocol Study, JADE REAL. J of Skin [Internet]. 2025 Nov. 10 [cited 2026 May 26];9(6):s618. Available from: https://skin.dermsquared.com/skin/article/view/3822